Open-Angle Glaucoma - Pipeline Review, H2 2016

Choose Licence

 

Open-Angle Glaucoma - Pipeline Review, H2 2016 Summary Global Markets Directs, Open-Angle Glaucoma - Pipeline Review, H2 2016?, provides an overview of the Open-Angle Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma - The report reviews pipeline therapeutics for Open-Angle Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Open-Angle Glaucoma therapeutics and enlists all their major and minor projects - The report assesses Open-Angle Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Open-Angle Glaucoma Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Open-Angle Glaucoma Overview 10 Therapeutics Development 11 Pipeline Products for Open-Angle Glaucoma - Overview 11 Pipeline Products for Open-Angle Glaucoma - Comparative Analysis 12 Open-Angle Glaucoma - Therapeutics under Development by Companies 13 Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes 15 Open-Angle Glaucoma - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Open-Angle Glaucoma - Products under Development by Companies 19 Open-Angle Glaucoma - Products under Investigation by Universities/Institutes 21 Open-Angle Glaucoma - Companies Involved in Therapeutics Development 22 Aerie Pharmaceuticals, Inc. 22 Allergan Plc 23 Amakem NV 24 Bausch & Lomb Incorporated 25 F. Hoffmann-La Roche Ltd. 26 Glaukos Corporation 27 Inotek Pharmaceuticals Corporation 28 Isarna Therapeutics GmbH 29 Kowa Company, Ltd. 30 Laboratoires Thea S.A. 31 Laboratorios Sophia S.A. de C.V. 32 Lee's Pharmaceutical Holdings Limited 33 Lexicon Pharmaceuticals, Inc. 34 Ocular Therapeutix, Inc. 35 Otsuka Holdings Co., Ltd. 36 Oxford BioMedica Plc 37 Sanofi 38 Santen Pharmaceutical Co., Ltd. 39 Senju Pharmaceutical Co., Ltd. 40 Sun Pharma Advanced Research Company Ltd. 41 Sylentis S.A.U. 42 ViSci Ltd. 43 Open-Angle Glaucoma - Therapeutics Assessment 44 Assessment by Monotherapy Products 44 Assessment by Combination Products 45 Assessment by Target 46 Assessment by Mechanism of Action 49 Assessment by Route of Administration 51 Assessment by Molecule Type 53 Drug Profiles 55 (bimatoprost + brimonidine tartarate + timolol maleate) - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 (bimatoprost + timolol maleate) - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 (carteolol hydrochloride + latanoprost) - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 (latanoprost + netarsudil mesylate) - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 (latanoprost + timolol maleate) - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 (latanoprost + trabodenoson) - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 AMA-0076 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG) - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 bamosiran - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 bimatoprost - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 bimatoprost SR - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 DE-117 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 decorin - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Glaucoma-GT - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 ISTH-0036 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 latanoprost - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 latanoprost - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 latanoprost SR - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 latanoprost SR - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 latanoprostene bunod - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 levobetaxolol hydrochloride - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 LX-7101 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 MAN-01 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 MGV-354 - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 netarsudil mesylate - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 OPA-6566 - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 PRO-067 - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 R-801 - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 RG-4929 - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 ripasudil - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 RO-5093151 - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 SAR-366234 - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 Sepetaprost - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 SNJ-1656 - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 trabodenoson - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 travoprost - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 travoprost SR - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 travoprost XR - Drug Profile 113 Product Description 113 Mechanism Of Action 113 R&D Progress 113 Open-Angle Glaucoma - Dormant Projects 115 Open-Angle Glaucoma - Discontinued Products 117 Open-Angle Glaucoma - Product Development Milestones 118 Featured News & Press Releases 118 Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting 118 Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension 118 Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting 119 Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week 119 Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System 120 Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System 121 Appendix 122 Methodology 122 Coverage 122 Secondary Research 122 Primary Research 122 Expert Panel Validation 122 Contact Us 122 Disclaimer 123

List of Tables Number of Products under Development for Open-Angle Glaucoma, H2 2016 11 Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Number of Products under Development by Companies, H2 2016 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Development by Companies, H2 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2016 21 Open-Angle Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 22 Open-Angle Glaucoma - Pipeline by Allergan Plc, H2 2016 23 Open-Angle Glaucoma - Pipeline by Amakem NV, H2 2016 24 Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H2 2016 25 Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 26 Open-Angle Glaucoma - Pipeline by Glaukos Corporation, H2 2016 27 Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016 28 Open-Angle Glaucoma - Pipeline by Isarna Therapeutics GmbH, H2 2016 29 Open-Angle Glaucoma - Pipeline by Kowa Company, Ltd., H2 2016 30 Open-Angle Glaucoma - Pipeline by Laboratoires Thea S.A., H2 2016 31 Open-Angle Glaucoma - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016 32 Open-Angle Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 33 Open-Angle Glaucoma - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 34 Open-Angle Glaucoma - Pipeline by Ocular Therapeutix, Inc., H2 2016 35 Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 36 Open-Angle Glaucoma - Pipeline by Oxford BioMedica Plc, H2 2016 37 Open-Angle Glaucoma - Pipeline by Sanofi, H2 2016 38 Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 39 Open-Angle Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016 40 Open-Angle Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 41 Open-Angle Glaucoma - Pipeline by Sylentis S.A.U., H2 2016 42 Open-Angle Glaucoma - Pipeline by ViSci Ltd., H2 2016 43 Assessment by Monotherapy Products, H2 2016 44 Assessment by Combination Products, H2 2016 45 Number of Products by Stage and Target, H2 2016 47 Number of Products by Stage and Mechanism of Action, H2 2016 50 Number of Products by Stage and Route of Administration, H2 2016 52 Number of Products by Stage and Molecule Type, H2 2016 54 Open-Angle Glaucoma - Dormant Projects, H2 2016 115 Open-Angle Glaucoma - Dormant Projects (Contd..1), H2 2016 116 Open-Angle Glaucoma - Discontinued Products, H2 2016 117


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining b...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBP...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein...

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximat...

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the re...

New Pharmaceuticals and Healthcare Reports